2.67
-0.06(-2.20%)
Currency In USD
| Previous Close | 2.73 |
| Open | 2.73 |
| Day High | 2.73 |
| Day Low | 2.64 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 2.91M |
| Average Volume | 3.16M |
| Market Cap | 340.58M |
| PE | -2.87 |
| EPS | -0.93 |
| Moving Average 50 Days | 2.79 |
| Moving Average 200 Days | 3.33 |
| Change | -0.06 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $123.67 as of July 12, 2025 at a share price of $2.67. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $853.04 as of July 12, 2025 at a share price of $2.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
GlobeNewswire Inc.
Jul 07, 2025 12:00 PM GMT
Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertiseVANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceut
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
GlobeNewswire Inc.
May 13, 2025 8:01 PM GMT
Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over
Absci to Report Business Updates and First Quarter 2025 Financial and Operating Results on May 13, 2025
GlobeNewswire Inc.
Apr 14, 2025 8:05 PM GMT
VANCOUVER, Wash. and NEW YORK, April 14, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for t